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Abstract 1 
Respiratory syncytial virus (RSV) is the main cause of bronchiolitis, the 2 
major cause of hospitalization in infancy. An ideal RSV vaccine would be 3 
effective in neonates, but the immune responses of infants differ markedly from 4 
those in adults, often showing a bias towards T helper 2 (Th2) responses and 5 
reduced interferon gamma (IFN-γ) production. We have previously developed 6 
recombinant RSV vectors expressing the IFN-γ and interleukin-4 (IL-4) that allow 7 
us to explore the role of these key Th1 and Th2 cytokines during infection. The 8 
aim of the current study was to explore whether immunomodulation of infant 9 
responses could enhance protection. Expression of IFN-γ by a recombinant RSV 10 
(rRSV/IFN-γ) vector attenuated primary viral replication in newborn mice without 11 
affecting the development of specific antibody or T cell responses. On challenge 12 
rRSV/IFN-γ mice were protected from the exacerbated disease observed in mice 13 
primed with wild type RSV; however, anti-viral immunity was not enhanced. 14 
Conversely, expression of IL-4 by recombinant RSV did not affect virus 15 
replication in neonates but greatly enhanced Th2 immune responses on 16 
challenge without affecting weight loss. These studies demonstrate that it is 17 
possible to manipulate the infant immune responses using cytokine-expressing 18 
recombinant viruses and that neonatal deficiency in IFN-γ responses may lead to 19 
enhanced disease during secondary infection. 20 
 21 
22 
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Introduction 1 
Respiratory syncytial virus (RSV) is the most important cause of viral lung 2 
infection in infants (31). The hospitalization rate in the USA is 17 per 1,000 3 
children with outpatient rates much higher (15) and re-infection in infancy is 4 
common (14). The mortality caused by RSV in developing countries and the high 5 
rates of hospitalization in industrialized countries means that the development of 6 
an RSV vaccine is an urgent health priority. A major problem in the development 7 
of an RSV vaccine is the requirement for efficacy in very early life; this is 8 
problematic because of the immaturity of the immune system in infancy (38). This 9 
immune immaturity decreases vaccine efficacy (29) and increases susceptibility 10 
to all respiratory viruses (34). 11 
In general, protection against viral infection is mediated by a balance of 12 
neutralizing antibody responses and long lasting virus specific CD8 T cell 13 
memory. Both of these compartments are severely impaired in infants. There are 14 
several aspects that contribute to the reduced immune response in early life. 15 
Total lymphocyte and dendritic cell numbers are significantly lower in neonates 16 
than adults (3). Microarchitectural structures thought to be crucial for antibody 17 
development (i.e. lymphoid follicles, follicular dendritic cell networks and germinal 18 
centers) are absent at birth and only form between a few days and a few weeks 19 
of age (13). The full repertoire of antigen presenting cells is only achieved several 20 
weeks after birth (32). Finally, the responses primed by infantile exposure to 21 
pathogens, or other inflammatory stimuli, are significantly altered compared to 22 
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adult responses, with memory responses dominated by the T helper 2 (Th2) arm 1 
of the immune system (2,3). 2 
Increased levels of IL-4, the archetypal Th2 cytokine, are associated with 3 
increased RSV disease severity in infancy (1,18,25). In addition, severe RSV 4 
infection is linked with the development of wheeze and asthma in later life (30), 5 
diseases that are classically linked to aberrant Th2 responses. Infection of 6 
neonatal mice with RSV results in the development of Th2 skewed immunity and 7 
increased disease severity when mice are re-infected with RSV as adults (8). In 8 
comparison RSV infection of adult mice results in a Th1 and CD8 T cell response 9 
and the subsequent development of protective immunity (28,35). It is therefore 10 
hypothesized that increased Th2 responses are detrimental to the outcome of 11 
neonatal RSV infection and reduction of Th2 responses and/or promotion of Th1 12 
responses would be beneficial. 13 
We have previously demonstrated that recombinant RSV expressing IFN-γ 14 
(RSV/IFN-γ) can be used to promote Th1 immunity in adult mice, attenuating viral 15 
replication without affecting immunogenicity (5). In contrast co-expression of IL-4 16 
by RSV (RSV/IL-4) causes defective T cell responses but does not affect viral 17 
clearance (6). On challenge RSV/IFN-γ primed adult mice show enhanced CD8 T 18 
cell recruitment, leading to immunopathology, whilst RSV/IL-4 primed mice show 19 
enhanced eosinophilia (16). The aim of the current study was to investigate the 20 
effects of cytokine modulation on the neonatal immune response to RSV. We 21 
found that RSV/IFN-γ was protective against the disease enhancing effects of 22 
neonatal RSV infection, whilst RSV/IL-4 significantly increased the Th2 skewing 23 
of the immune response without worsening disease. 24 
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 1 
Materials and Methods 2 
Virus stocks & Mouse Infection.  3 
RSV (strain A2) was obtained from the ATCC and recombinant RSV 4 
expressing mouse IFN-γ (RSV/IFN-γ) or IL-4 (RSV/IL-4) or wildtype recombinant 5 
virus (RSV/wt) were made as described in (5,6). Time mated pregnant BALB/c 6 
mice (Harlan, Iscoed, UK) were purchased at <14d gestation and pups were 7 
weaned at 3wk old. Mice were infected intranasally (i.n.) with 4x104 FFU/g body 8 
weight virus at 4 days (neonatal ~ 105) under isoflurane anesthesia. Secondary 9 
RSV challenge was given i.n. at 8 weeks post priming, with 106 FFU in 100µl. 10 
Weight was measured daily to monitor disease severity. All work was approved 11 
and licensed by the UK Home Office. Experiments were performed n≥2 times 12 
with n≥4 mice per experiment. 13 
 14 
Quantification of Viral RNA.  15 
RNA was extracted from the lung using RNA stat-60 (AMS Biotech Ltd.) 16 
and cDNA was generated with random hexamers using Omniscript RT (Qiagen). 17 
Real time PCR was carried out with for a sequence in the RSV L gene using 900 18 
nM forward primer (5’-GAACTCAGTGTAGGTAGAATGTTTGCA-3’), 300 nM 19 
reverse primer (5’-TTCAGCTATCATTTTCTCTGCCAAT-3’) and 100 nM probe 20 
(5’-FAM-TTTGAACCTGTCTGAACAT-TAMRA-3’) on an ABI Prism 7000 21 
Sequence Detection System. This detects viral genomic RNA,  viral anti-genomic 22 
RNA and intracellular RSV L mRNA, referred to here as RSV L RNA. 23 
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 1 
Cell Recovery.  2 
Collection of bronchoalveolar lavage (BAL) for cells and supernatants, the 3 
harvesting of lung tissues was carried out as previously described (7). For the 4 
preparation of lung mash supernatants, lungs were homogenized through 100 5 
µm cell strainers (BD Pharmingen) and washed through with a 1ml volume of 6 
RPMI five times, following centrifugation this supernatant was retained for ELISA 7 
analysis. After the removal of the supernatants from all tissues, cells were treated 8 
with red blood cell lysis buffer for 5 minutes, then DNAse I (40μg/ml)/Collagenase 9 
(50μg/ml) in RPMI 1640 (10% FCS) for 5 minutes at room temperature to remove 10 
clumps, finally they were resuspended in RPMI. Cell viability was assessed by 11 
trypan blue exclusion, and total cell numbers were counted by disposable 12 
multiwell haemocytometer (Immunesystems, UK). Airway cells were 13 
differentiated by H&E staining of BAL cell samples.  14 
 15 
Flow Cytometry. 16 
Prior to staining cells were blocked with CD16/32 (Fc Block, BD). For 17 
surface staining antibodies against the surface markers CD4, CD8, CD3, CD69, 18 
CD11b,CD11c, CD80, CD86, MHCII, CD62L, CD44 and DX5 (BD) were added in 19 
1:100 dilution for 30 minutes on ice. RSV specific CD8 cells were characterized 20 
using the RSV M2 MHC class I pentamer (SYIGSINNI; Proimmune). Gating for 21 
lymphocytes was determined by back gating on CD3/CD8 double positive cells. 22 
For the detection of intracellular cytokines, cells were incubated with 50ng/ml 23 
PMA, 500ng/ml ionomycin and 10μg/ml Brefeldin A for 4 hours at 37°C. Samples 24 
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were permeabilised with 0.5% saponin in PBS for 10 minutes. Anti-cytokine 1 
antibodies (anti-IFN-γ, anti-IL-4:BD) or isotype controls were added for a further 2 
20 minutes at room temperature. Cells were analyzed on a CyAn ADP (Dako) 3 
flow cytometer collecting data on at least 50,000 events. 4 
 5 
Cytokine ELISA.  6 
Cytokine levels were assessed from BAL and lung mash supernatants. 7 
ELISA plates (Nunc) were coated with capture antibody (anti IL-4, IL-5 or IFN-γ: 8 
BD) overnight at 4°C. Wells were washed and blocked with 1% BSA for 1h at 9 
room temperature. 100ul of sample or standard was added to blocked wells for 10 
2h. Bound cytokine was detected by using biotinylated anti-cytokine antibody, 11 
avidin horseradish-peroxidase and tetramethylbenzidine. Color development was 12 
terminated with 2N H2SO4, and OD read at 490nm. The concentration of cytokine 13 
was determined from the standard curve. 14 
 15 
RSV-specific antibody ELISA.  16 
Serum antibody was assessed by ELISA. Antigen was prepared by 17 
infecting HEp-2 cells with RSV at 1 FFU/cell. Microtiter plates were coated 18 
overnight with 100μl of a 1:500 dilution of either RSV or HEp-2 antigen. After 19 
blocking with 1% BSA for 1h, dilutions of test samples were added for a further 20 
1h. Bound antibody was detected using peroxidase-conjugated rabbit anti-mouse 21 
Ig (Dako) and o-phenylenediamine as a substrate. Color development was 22 
blocked with 2M H2SO4, and OD read at 490nm. RSV-specific antibody was 23 
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determined by subtracting the RSV absorbance from the HEp-2 absorbance for 1 
the same sample. Specific isotypes were measured following the same protocol, 2 
changing the primary antibody. Total, non specific, IgE was measured according 3 
to manufacturer’s instructions (BD). 4 
 5 
Statistical analysis.  6 
Results are expressed as mean ± S.E.M.; statistical significance was 7 
calculated by ANOVA followed by Tukey tests when there were greater than 3 8 
groups and t tests for the comparison of 2 groups using GraphPad Prism 9 
software. 10 
11 
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Results 1 
Primary neonatal infection with recombinant RSV expressing either IFN-γ 2 
or IL-4. We have previously described the construction and characterization of 3 
recombinant RSVs expressing either IFN-γ or IL-4 (16). These viruses grow with 4 
similar kinetics to wild type viruses in both human and mouse cell lines (data not 5 
shown). In adult BALB/c mice RSV/IL-4 grows at wildtype levels whilst RSV/IFN-γ 6 
is attenuated approximately 10-fold (5,6,16). To asses the effect of these viruses 7 
on neonates, mice less than 1 week of age were infected with 8x104 FFU RSV/wt, 8 
RSV/IFN-γ or RSV/IL-4 intranasally (i.n.). Weight was monitored daily as a 9 
measure of disease severity (Figure 1a). Neonates gained weight rapidly from 10 
day 0 of infection, doubling their weight by day 8 post infection; there was no 11 
significant change in weight gain following infection.  12 
RNA was extracted from the lungs on days 2, 4, 7 and 14 post infection 13 
and levels of RSV L RNA assessed by real time PCR (Figure 1b). Following 14 
infection with RSV/wt or RSV/IL-4 there was a peak of viral RNA detected on 15 
days 2 and 4, which declined on d7 and was cleared by d14. There was no 16 
significant difference between RSV/wt and RSV/IL-4 infection. On day 2, the level 17 
of total RSV L RNA from RSV/IFN-γ infected mice were approximately half those 18 
seen in the other groups and on day 4 post infection they were 3-fold lower than 19 
RSV/wt (p<0.05). There was no RSV L RNA detectable in the lungs of RSV/IFN-γ 20 
infected mice from day 7 onwards, indicating that viral clearance was quicker 21 
than after RSV/wt or RSV/IL-4 infection. 22 
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As has previously been seen in adult mice, infection with RSV/IFN-γ 1 
caused a significant increase in lung IFN-γ concentration on day 2 post infection 2 
compared to infection with RSV/wt, RSV/IL-4 or naïve mice (Figure 1c, p<0.01). 3 
Likewise RSV/IL-4 caused a significant peak of IL-4 on day 2 post infection 4 
compared to the other groups (Figure 1d, p<0.05). Therefore, the recombinant 5 
RSV are infectious in neonates inducing local cytokine production which alter the 6 
viral clearance kinetics. 7 
 8 
Effect of the co-expression of IL-4 and IFN-γ on cellular recruitment during 9 
primary neonatal RSV infection. We were interested in the effect of recombinant 10 
viral vectors on neonatal immune responses. Lung cells were collected on days 4, 11 
7 and 14 post infection from neonatal mice infected with RSV/wt, RSV/IFN-γ, 12 
RSV/IL-4 or left uninfected. The total number of cells in the lung increased with 13 
age and RSV infection did not significantly alter this at any timepoint (Figure 2a). 14 
Infection did not affect lymphocyte percentages in the lungs, which went from 15 
approximately 30% on day 4 post infection to approximately 60% at day 14 post 16 
infection in all cases (Figure 2b). 17 
The effect of cytokine on antigen presenting cells in the neonatal lung was 18 
also assessed. There were no differences in the numbers of CD11c+CD11b+ 19 
dendritic cells recruited to the lung following infection (data not depicted). 20 
However there were significantly more CD11c+CD11b- macrophages in the 21 
lungs on day 4 post infection in the RSV/IFN-γ infected mice than RSV/wt or 22 
RSV/IL-4 infection (Figure 2c, p<0.05). The activation status of these cells was 23 
also significantly increased by RSV/IFN-γ infection, measured by MHCII (Figure 24 
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2d), CD80 (Figure 2e) and CD86 (Figure 2f). NK cell numbers (CD3-DX5+) 1 
increased with age, and RSV infection had little effect on this (Figure 2g). The 2 
cell surface protein CD69, is a marker of activation on both NK and T cells (39). 3 
On day 4 post infection only mice infected with RSV/IFN-γ had an increased 4 
percentage of CD69+ NK cells in their lungs (p<0.05, Figure 2h). On subsequent 5 
days there was no difference between RSV infected animals and naïve animals 6 
irrelevant of the virus used. 7 
The number of T cells in the lungs also increased from day 4 to 14 post 8 
infection (day 18 of life). On day 4 post infection, naïve mice had approximately 9 
1.2 x 104 CD4 T cells (Figure 3a) and approximately 4.8 x 103 CD8 T cells 10 
(Figure 3b). By day 14 after infection, day 18 of age, the number of CD4 T cells in 11 
the naïve lung had risen to approximately 5.3 x 104 cells per lung, whilst the 12 
number of CD8 T cells was 1 x 104 cells per lung. As with total cell and 13 
lymphocyte recruitment infection with RSV/wt or either of the recombinant viruses 14 
seemed to have little effect on the pattern of T cell recruitment. 15 
In order to determine whether infection affected T cell activity rather than 16 
affecting total recruitment, we analyzed the expression of a number of cell 17 
surface markers. CD62L and CD44 can be used to differentiate effector T cells 18 
(CD44hiCD62Llo) and memory T cells (CD44hiCD62Lhi) (37). Very few memory 19 
cells were seen in the lungs at any time point but there were observable changes 20 
in the percentage of effector T cells with infection. The co-expression by RSV of 21 
either IFN-γ or IL-4 caused an increase in the proportion of CD4 effector cells on 22 
day 4 p.i. compared to RSV/wt infected and naïve mice (Figure 3c). By day 7 p.i. 23 
this difference was not observable but on day 14 p.i. all infected mice showed a 24 
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significant increase in the percentage of effector CD4 T cells compared to naïve 1 
mice and at this timepoint there was no difference between the different viral 2 
infections (p<0.05). Expression of CD69 by CD4 T cells followed a similar pattern 3 
to CD44. On day 4 post infection RSV/IL-4 and RSV/IFN-γ infected mice had 4 
higher percentage of CD69+ CD4 T cells than RSV/wt (Figure 3d). On day 14 5 
there were slightly elevated percentages in infected mice compared to naïve 6 
mice. 7 
There was no significant difference in CD44 expression by CD8 cells on 8 
d4 post infection. On d7 and d14 post infection, RSV/IFN-γ had significantly 9 
fewer CD8 effector cells than RSV/wt or RSV-IL-4 (Figure 3e, p<0.05). Infection 10 
with RSV/IFN-γ or RSV/IL-4 caused significant upregulation of CD69 on CD8 T 11 
cells compared to infection with RSV/wt on day 4 post infection (p<0.05). On 12 
subsequent days RSV/wt infected neonates had increased CD69+ CD8 T cells, 13 
on day 14 post infection there were significantly more active CD8 T cells than any 14 
other group (p<0.05). At this timepoint the percentages of activated CD8 T cells 15 
in mice infected with RSV/IFN-γ or RSV/IL-4 were similar to those found in naïve 16 
mice (Figure 3f). 17 
On day 14 post infection, after viral clearance from the lungs, CD4 T cells 18 
were stimulated with PMA and ionomycin and stained for intracellular IL-4 and 19 
IFN-γ. The number of IFN-γ+ CD4 T cells was low in all groups, however both 20 
RSV/wt and RSV/IFN-γ had significantly more than naïve mice (p<0.05, Figure 21 
4a). RSV/IL-4 infection did not result in an increased number IFN-γ+ CD4 T cells. 22 
RSV/wt and RSV/IL-4 infection resulted in significantly increased numbers of IL-23 
4+ CD4 T cells in the lungs compared to RSV/IFN-γ infection (Figure 4b, p<0.05). 24 
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An MHC class I tetramer containing the immunodominant RSV specific 1 
CD8 T cell epitope (SYIGSINNI) located in the M2-1 protein (23) was also used 2 
on d14 to determine the number of RSV-specific CD8 T cells. RSV/wt and 3 
RSV/IFN-γ infection resulted in the recruitment of more RSV specific CD8 T cells 4 
than RSV/IL-4 (Figure 4c). By contrast to the cellular responses, similar serum 5 
levels of RSV specific antibody were detected in mice infected with all three 6 
viruses at day 14 post infection (Figure 4d). From this we observe that cytokine 7 
co-expression subtly alters the profile of cells recruited during neonatal infection. 8 
 9 
IFN-γ co-expression during primary infection prevents the development of 10 
enhanced disease on challenge as adults. As both recombinant viruses altered 11 
the immune response to neonatal RSV infection we hypothesized that secondary 12 
immune responses and disease outcome would also be affected. Neonatal mice 13 
were primed and then re-challenged 8 weeks after priming with 106 FFU of 14 
wildtype RSV. As we have previously reported (8) neonatal infection with RSV/wt 15 
resulted in weight loss on secondary infection, peaking on day 4 with recovery 16 
around day 7 (Figure 5a). Mice primed with RSV/IL-4 also lost weight on 17 
challenge, with a similar profile to RSV/wt primed mice but RSV/IFN-γ primed lost 18 
significantly less weight than the RSV/IL-4 primed mice on days 2-5 post infection 19 
(p<0.05). 20 
In spite of the change in weight loss, viral loads were similar in all three 21 
groups on day 4 post infection and no viral RNA was detectable on days 7 or 14 22 
post challenge (Figure 5b). RSV/IFN-γ primed animals had significantly reduced 23 
anti-RSV antibody titer (Figure 5c, p<0.05). Interestingly neonatal priming with 24 
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RSV/IFN-γ resulted in reduced concentrations of both IFN-γ (Figure 5d) and IL-4 1 
(Figure 5e) in the BAL on day 4 post infection compared to and RSV/IL-4 2 
(p<0.05).  3 
 4 
Cellular responses during secondary infection. The numbers of CD4, CD8 5 
and NK cells in the lungs were assessed on days 4 and 7. There were 6 
significantly more CD4 T cells in the lungs of RSV/wt primed mice on day 7 post 7 
challenge compared to mice primed with RSV/IFN-γ or RSV/IL-4 (Figure 6a, 8 
p<0.01). The CD4 cells were significantly more activated (CD69+, Figure 6b, 9 
p<0.05) and produced more IFN-γ (Figure 6c, p<0.01). There were no differences 10 
in the number, activation status or IFN-γ production of the CD4 T cells from 11 
RSV/IL-4 or RSV/IFN-γ primed mice. However, there were significantly more IL-12 
4+ CD4 T cells in the lungs of mice primed with RSV/IL-4 on day 4 post 13 
challenge than in either RSV/IFN-γ or RSV/wt primed mice (Figure 6d, p<0.01). 14 
CD8 T cell recruitment into the lungs peaked on day 7 post challenge in all 15 
groups with recruitment being greatest after priming with RSV/wt compared to 16 
RSV/IFN-γ or RSV/IL-4 (Figure 6e, p<0.01). There was no significant difference 17 
in the activation of these cells as measured using CD69 (Figure 6f), but there 18 
were significantly more RSV specific (Figure 6g, p<0.01) and IFN-γ producing 19 
(Figure 6h, p<0.01) CD8 T cells following RSV/wt priming on day 7 post 20 
challenge. On day 4 post challenge RSV/IL-4 and RSV/wt primed mice had 21 
significantly more lung NK cells than RSV/IFN-γ primed mice (Figure 6i, p<0.01). 22 
On day 7 post infection NK cells numbers had greatly reduced and were similar 23 
in all three primed groups. 24 
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 1 
IL-4 priming results in significant enhancement of Th2 responses on 2 
challenge. The disease seen on re-challenge of mice primed with RSV in the 3 
neonatal period has been described as the result of a Th2 skewed immune 4 
response (8). Eosinophil (Figure 7a) and neutrophil (Figure 7b) recruitment was 5 
mainly observed in mice primed neonatally with RSV/wt or RSV/IL-4, but not 6 
RSV/IFN-γ. Co-expression of IL-4 during neonatal infection caused an 7 
approximately 4 fold increase in airway eosinophilia on days 4 and 2.5 fold 8 
increase on day 7 post challenge compared to RSV/wt infection (p<0.01). IL-5 is 9 
a key cytokine in the recruitment and survival of eosinophils and on day 4 post 10 
challenge and levels of IL-5 were significantly lower in RSV/IFN-γ treated animals 11 
compared to the other two groups (Figure 7c, p<0.05). 12 
As an additional readout of the Th1/Th2 balance of re-challenged mice, 13 
RSV specific antibody subtypes were determined on day 7 post challenge. IgG2a 14 
responses were slightly, but not significantly, higher in RSV/wt primed mice 15 
compared to RSV/IL-4 primed animals (Figure 7d). RSV- specific IgG1 (Th2 16 
associated subtype) responses were significantly higher in mice primed with 17 
RSV/IL-4 than those seen with either RSV/wt (p<0.05) or RSV/IFN-γ infections 18 
(Figure 7e, p<0.001). Serum was also tested for the presence of total IgE on day 19 
7 post challenge. Neonatal priming with RSV/IL-4 resulted in significantly 20 
elevated levels of total IgE compared to priming with RSV/wt or RSV/IFN-γ 21 
(Figure 7f, p<0.05). Interestingly all three neonatally primed groups had 22 
significantly elevated levels of serum IgE compared to naïve mice or mice primed 23 
as adults, in which the development of serum IgE is not normally observed (data 24 
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not depicted). Therefore the co-expression of IL-4 by RSV during primary 1 
neonatal enhances the Th2 nature of the secondary response. 2 
 3 
Discussion 4 
The aim of the current study was to investigate the effects of cytokine 5 
modulation on the neonatal immune response to RSV, in the context of improving 6 
neonatal vaccine efficacy. As seen previously (5,16), reduced viral titers were 7 
observed following infection with the RSV/IFN-γ virus compared to RSV/wt and 8 
RSV/IL-4. This could be due to the insertion of the IFN-γ cDNA within the RSV 9 
genome, affecting replication. However, it has been shown that RSV can accept 10 
inserted genes with little effect on genome transcription or replication (5). A 11 
similar phenotype of reduced viral load is observed with a recombinant RSV that 12 
expresses IL-18; in this case, replication occurs normally in vitro but is reduced in 13 
vivo (17). It is possible that both RSV recombinants have impaired growth in vivo 14 
but that IL-4 expression leads to impaired antiviral defense and enhanced viral 15 
replication that matches the impaired growth caused by gene insertion (6). 16 
However, the simplest explanation is that IFN-γ expression decreased viral load 17 
because it augments anti-viral immunity. 18 
It has been reported that the enhanced disease seen after re-challenge of 19 
RSV-primed neonates is characterized as Th2 skewed with increased IL-4 20 
secreting CD4 T cells, eosinophilia and IL-13 production (8,10). Many of the 21 
features of the immune response that were increased by RSV/IL-4 priming, for 22 
example IgE and eosinophilia have been postulated to be important in severe 23 
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RSV disease. In infants, IgE levels correlate with the severity of disease (36) and 1 
IgE is required for enhanced airway hyperresponsiveness in neonatally primed 2 
mice (9). In a similar fashion eosinophilia has been associated with enhanced 3 
lung disease following both RSV infection (20) and during asthma and allergy 4 
(19).  5 
Whilst over-expression of IL-4 during neonatal priming resulted in 6 
increased IgE and eosinophilia on challenge it did not result in increased disease. 7 
The role of eosinophils in allergic airway disease is currently being re-evaluated 8 
with the demonstration that they have a beneficial role in innate anti-viral 9 
immunity and are dispensable in the development of asthma (12,22,27). 10 
Furthermore, depletion of CD4 cells during neonatal murine RSV infection only 11 
marginally reduces weight loss, despite eliminating eosinophilia (35). We have 12 
also observed that CD8 T cells are a critical determinant of disease, but there 13 
may be a balance between protective and pathogenic CD8 T cells (33). These 14 
data indicate that whilst Th2 responses are often seen during enhanced RSV 15 
disease, their presence does not directly correlate with severity. 16 
Despite a lack of disease enhancement with increased IL-4 expression, 17 
priming neonates with RSV/IFN-γ abrogated weight loss after re-challenge. 18 
Recently Lee, et al. demonstrated that the administration of recombinant IFN-γ 19 
during neonatal infection prevented the development of airway 20 
hyperresponsiveness or eosinophilia on re-challenge (24). The proposed 21 
mechanism for this was an increase in Th1 memory responses and a reduction in 22 
Th2 memory responses. RSV/IFN-γ, however, did not increase recruitment of 23 
IFN-γ secreting CD4 cells or the production of IFN-γ during re-challenge; 24 
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suggesting that it did not enhance Th1 cell development. Therefore the data 1 
presented here suggest there may be an alternative mechanism of protection. 2 
Viral infection in adults is known to cause long term changes in lung 3 
resident APCs including macrophages (11). Interestingly infection of neonates 4 
with RSV/wt did not result in significant maturation and activation of these cells in 5 
vivo. However, priming with IFN-γ caused rapid and significant maturation of 6 
macrophages in the neonatal lung. Therefore, one possible mechanism of 7 
protection for RSV/IFN-γ could be through maturation of the innate components 8 
of lung immunity. 9 
On re-challenge, RSV/IFN-γ priming resulted in significantly reduced 10 
neutrophil and NK cell recruitment at the peak of weight loss. This suggests that, 11 
along with T cells, cells of the innate immune system contribute to weight loss. In 12 
infantile bronchiolitis, neutrophils have been observed to be the major cell type in 13 
the airways of RSV infected infants (26). The activation of NK cells by over 14 
expression of IL-18 enhances disease and weight loss during primary RSV 15 
infection (17) and NK cells are the major source of early IFN-γ production during 16 
RSV infection (21). Both NK cells and neutrophils are activated and recruited to 17 
the lungs by a similar range of mediators, produced primarily by resident lung 18 
macrophages in RSV infection, supporting the idea that macrophages may be 19 
involved in neonatally primed disease (4,28).  20 
We conclude that exogenous cytokine expression can modulate the 21 
neonatal immune response and alter the immunological memory generated 22 
during early childhood. Importantly the ability of IFN-γ to protect in this neonatal 23 
model contrasts to the results in adult mice, where RSV/IFN-γ enhances disease 24 
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during re-challenge (16). It is therefore necessary to consider the age of first 1 
priming in the development of vaccines, since the age at which the vaccine is 2 
administered is critical in determining the pattern of immune response that results.  3 
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Figure legends 1 
 2 
Figure 1: Recombinant virus replication and cytokine production in 3 
primary neonatal infection. 4 day old BALB/c mice were infected with 8 x 104 4 
FFU of RSV/wt (■, black bars), RSV/IFN-γ (▲, hatched bars), RSV/IL-4 (○, lined 5 
bars) i.n. or left naive (◊, open bars). Weight was monitored daily and weight 6 
change compared to weight prior to infection was plotted (A). TaqMan PCR for 7 
RSV L RNA was carried out on RNA from lungs were collected on days 2, 4, 7 8 
and 14 post infection (B). Lung supernatants were taken on days 2 and 4 post 9 
infection and the concentrations for IFN-γ (C) and IL-4 (D) determined by ELISA. 10 
Data representative of 3 experiments, points represent n = 5 ± SEM mice per 11 
group, * p<0.05, **p<0.01. 12 
 13 
Figure 2: The recruitment and activation of innate immune cells is 14 
altered by viral cytokine expression. 15 
4 day old BALB/c mice were infected with 8 x 104 FFU of RSV/wt (■), 16 
RSV/IFN-γ (▲), RSV/IL-4 (○) i.n. or left naive (◊). Cells were taken from lungs 17 
and total lung cell number after homogenization (A) and percentage lymphocytes 18 
(B) determined on days 4, 7 and 14 post infection. Lung macrophages 19 
(CD11c+CD11b- cells) were characterized by flow cytometry, measuring number 20 
(C), MHCII (D), CD80 (E) and CD86 (F) expression. Total NK cells (CD3-DX5+) 21 
(G) and activation of NK cells/CD69+ (H) were also measured. Data 22 
representative of 2 experiments, points represent n = 5 ± SEM mice per group. 23 
 24 
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Figure 3: Neonatal T cell responses are altered by viral cytokine 1 
expression. 4 day old BALB/c mice were infected with 8 x 104 FFU of RSV/wt 2 
(■), RSV/IFN-γ (▲), RSV/IL-4 (○) i.n. or left naive (◊). Cells were taken from 3 
lungs and total CD4 (A), CD8 (B) T cells were measured on days 4,7 and 14 post 4 
infection by flow cytometry. CD62l-CD44+ memory (C, E) and CD69+ activated 5 
(D, F) CD4 and CD8 cells respectively were also measured at the same 6 
timepoints. Data representative of 2 experiments, points represent n = 5 ± SEM 7 
mice per group. 8 
 9 
Figure 4: T cell cytokine production and RSV specific antibody 10 
responses following recombinant RSV infection. 4 day old BALB/c mice were 11 
infected with 8 x 104 FFU of RSV/wt (■, black bars), RSV/IFN-γ (▲, hatched 12 
bars), RSV/IL-4 (○, lined bars) i.n. or left naive (◊, open bars). On day 14 post 13 
infection PMA/ionomycin stimulated CD4 T cells were stained for the intracellular 14 
presence of IFN-γ (A) and IL-4 (B). At the same timepoint CD8 T cells were 15 
stained with a RSV-M2 specific pentamer (C). Serum was taken at 14 days post 16 
infection and the level of RSV specific Ig determined by ELISA (D). Data 17 
representative of 2 experiments, points represent n = 5 ± SEM mice per group, * 18 
p<0.05, **p<0.01. 19 
 20 
Figure 5: IFN-γ expression in the neonatal period protects against 21 
exacerbated weight loss. 4 day old BALB/c mice were infected i.n. with 8 x 104 22 
FFU of RSV/wt (■, black bars), RSV/IFN-γ (▲, hatched bars), RSV/IL-4 (○, lined 23 
bars). They were challenged with 106 FFU of wildtype RSV A2 i.n. at 8 weeks of 24 
Harker et al. J.Virol 
Early life immunomodulation by recombinant virus 26
age. After challenge, weight was monitored daily and plotted against their starting 1 
weight (A). On day 4 post challenge RNA was extracted from the lungs and the 2 
amount of RSV L RNA determined by real time PCR (B). Total RSV-specific Ig 3 
was measured in serum at d7 (C). BAL supernatants were taken on days 4 and 7 4 
to determine the levels of IFN-γ (D) and IL-4 (E) by ELISA. Data representative of 5 
2 repeats, points represent n = 5 ± SEM mice per group, **p<0.01, *** p<0.001. 6 
 7 
Figure 6: T cell responses in the lungs on challenge. 4 day old BALB/c 8 
mice were infected i.n. with 8 x 104 FFU of RSV/wt (solid bars), RSV/IFN-γ 9 
(hatched bars) or RSV/IL-4 (lined bars). They were challenged with 106 FFU of 10 
wildtype RSV A2 i.n. at 8 weeks of age. Lung CD4 T cell numbers (A) and 11 
activation (B) and the intracellular expression of IFN-γ (C) and IL-4 (D) were 12 
measured on days 4 and 7 post infection. Lung CD8 T cell number (E), activation 13 
(F), M2 specificity (G) and intracellular IFN-γ expression following stimulation (H) 14 
and NK cell numbers (I) were measured at the same timepoints. Data 15 
representative of 2 repeats, points represent n = 5 ± SEM mice per group, * 16 
p<0.05, **p<0.01. 17 
 18 
Figure 7: Th1/Th2 balance of the recall response. 4 day old BALB/c 19 
mice were infected i.n. with 8 x 104 FFU of RSV/wt (■, black bars), RSV/IFN-γ (▲, 20 
hatched bars), RSV/IL-4 (○, lined bars). They were challenged with 106 FFU of 21 
wildtype RSV A2 i.n. at 8 weeks of age. BAL was carried out on days 4 and 7 22 
post infection and the number of airway eosinophils (A) and neutrophils (B) 23 
recruited to the lung determined by H&E staining. IL-5 concentration in BAL 24 
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supernatants was determined by ELISA (C). Serum was taken on day 7 post 1 
challenge and the levels of RSV specific IgG2a (D), IgG1 (E) and total serum IgE 2 
(F) were quantified by ELISA. Data representative of 2 repeats, points represent 3 
n = 5 ± SEM mice per group, * p<0.05, **p<0.01, ***p<0.001.  4 
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